Biotech beauty company Debut, based in San Diego, has recently secured a notable investment of $20 million aimed at revolutionizing its AI-driven ingredient discovery platform and expanding its formulation business, particularly in Asia. This latest funding round attracted renowned investors including Fine Structure Ventures, EDBI, Wealthberry, L’Oréal, GS Futures, Sandbox Industries, and Material Impact. With a total of $85 million raised to date, Debut is gearing up to enhance skin longevity innovations while scaling its operations in the U.S. and across Asia.
The crux of Debut’s focus lies in pioneering next-generation ingredients that address the 14 hallmarks of aging. Joshua Britton, the company’s founder and CEO, emphasizes the shift from traditional anti-aging slogans to a new paradigm centered on skin longevity. He highlights that this approach necessitates tackling 44 different markers of skin aging, posing a significant challenge. Britton understands the importance of thorough scientific research and meticulous ingredient production, noting that they are sifting through 50 billion potential ingredients to discover those that will ultimately empower various beauty brands.
With plans to enter the Asian market, Debut has set its sights on Singapore as its initial location. The company intends to collaborate with leading brands in the region, creating custom ingredients and formulations specifically tailored for longevity in skincare. Britton underscores that the fusion of artificial intelligence with a deep understanding of skin biology allows for the development of personalized formulation solutions that were previously unattainable, reflecting the unique needs of different geographical markets.
In addition to ingredient innovation, Debut has ventured into contract manufacturing, aiming to make biotech ingredients accessible to a broader audience. The company signed a significant agreement with L’Oréal last July to develop over a dozen bio-identical ingredients set to replace conventionally sourced components in various global beauty and personal care lines. This partnership marked a pivotal moment for both parties, especially following L’Oréal’s $40 million investment through its venture arm, Bold.
Debut has also launched its own skincare brand, Deinde, in January 2024, which Britton notes is performing exceptionally well, on track to meet or surpass targets this year. This brand aligns with the company’s vision of integrating cutting-edge biotechnology into everyday beauty products, showing a commitment to quality and effectiveness that resonates with consumers.
As Debut continues to expand its reach and innovate within the beauty industry, its mission remains clear: to create high-performing and differentiated ingredients that redefine skincare. By harnessing the power of AI alongside deep scientific insights, Debut is positioned to lead the charge in the biotech beauty sector, making sustainable and effective skincare solutions widely available and transforming how consumers approach aging and skincare.